Two Seas Capital LP boosted its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 624.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,896,136 shares of the company's stock after purchasing an additional 2,496,136 shares during the period. Sotera Health comprises approximately 3.1% of Two Seas Capital LP's holdings, making the stock its 8th largest holding. Two Seas Capital LP owned about 1.02% of Sotera Health worth $39,619,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Xponance Inc. raised its stake in Sotera Health by 6.0% in the fourth quarter. Xponance Inc. now owns 17,495 shares of the company's stock worth $239,000 after buying an additional 989 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Sotera Health by 164.3% during the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after acquiring an additional 1,140 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Sotera Health by 37.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after acquiring an additional 1,640 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Sotera Health by 10.6% in the 4th quarter. Bank of Montreal Can now owns 18,184 shares of the company's stock valued at $249,000 after purchasing an additional 1,740 shares during the period. Finally, Quarry LP bought a new stake in shares of Sotera Health during the fourth quarter valued at approximately $28,000. Institutional investors own 91.03% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on SHC. Barclays decreased their price objective on Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their target price for the stock from $14.00 to $17.00 in a research report on Monday, May 5th. Finally, Piper Sandler lowered their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $15.80.
View Our Latest Stock Report on SHC
Sotera Health Stock Down 0.8%
Shares of NASDAQ SHC traded down $0.10 during trading on Monday, reaching $12.16. The company had a trading volume of 664,349 shares, compared to its average volume of 1,205,524. The business's 50-day moving average is $11.65 and its 200 day moving average is $12.70. Sotera Health has a 12-month low of $9.53 and a 12-month high of $17.08. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The stock has a market cap of $3.45 billion, a PE ratio of 48.64 and a beta of 1.88.
Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company had revenue of $254.52 million for the quarter, compared to the consensus estimate of $245.56 million. During the same quarter in the prior year, the firm earned $0.13 earnings per share. Sotera Health's revenue was up 2.6% on a year-over-year basis. As a group, equities analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.
About Sotera Health
(
Free Report)
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Featured Stories
Before you consider Sotera Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sotera Health wasn't on the list.
While Sotera Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
